Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy.

ABSTRACT:

Background

Metastatic small bowel adenocarcinoma (SBA) has a poor prognosis. Due to its rarity, high-quality data are lacking to guide treatment. This retrospective analysis was conducted to help characterize the treatment options for patients with metastatic SBA while providing clinically meaningful prognostic information.

Patients and methods

In total, 437 patients who initially presented with or developed metastatic SBA between September 1977 and September 2019 were identified from the MD Anderson Tumor Registry. Clinical data were collected from review of the medical record. Overall response rates (ORR), time to progression (TTP), and overall survival (OS) were assessed across various treatments and treatment lines.

Results

The median OS from diagnosis of metastat

SUBMITTER: Bhamidipati D 

PROVIDER: S-EPMC8111574 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature